Comparative Pharmacology
Head-to-head clinical analysis: JENCYCLA versus TRI LO MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENCYCLA versus TRI LO MILI.
JENCYCLA vs TRI-LO-MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary axis; norgestimate binds to progesterone receptors, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.
One tablet orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
8-12 hours; prolonged to 24 hours in severe hepatic impairment
Terminal elimination half-life: 20-24 hours; allows once-daily dosing for contraceptive efficacy.
Renal: 35-45% unchanged; biliary/fecal: 50-60% as metabolites
Renal: approximately 50% as metabolites; biliary/fecal: approximately 40% as metabolites; 10% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive